KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  title={KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.},
  author={Astrid Li{\`e}vre and Jean Baptiste Bachet and Delphine Le Corre and Val{\'e}rie Boige and Bruno Landi and Jean-François Emile and Jean-François C{\^o}t{\'e} and Gorana Tomasic and Christophe Penna and Michel Ducreux and Philippe Rougier and Fr{\'e}d{\'e}rique M Penault-Llorca and Pierre Laurent-Puig},
  journal={Cancer research},
  volume={66 8},
The anti-epidermal growth factor receptor (anti-EGFR) cetuximab has been proven to be efficient in metastatic colorectal cancer. The molecular mechanisms underlying the clinical response to this drug remain unknown. Genetic alterations of the intracellular effectors involved in EGFR-related signaling pathways may have an effect on response to this targeted therapy. In this study, tumors from 30 metastatic colorectal cancer patients treated by cetuximab were screened for KRAS, BRAF, and PIK3CA… 

Figures and Tables from this paper

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
KRAS mutations are associated with cetuximab failure in EGFR FISH+ mCRC, even if it does not preclude response, and the rarity of MET and IGF1R gene amplification suggests a marginal role in primary resistance.
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
BRAF and PIK3CA mutations would seem to be independent predictors of anti-EGFR therapy effectiveness and could be taken into consideration during treatment decision making.
KRAS Mutational Status as a Predictor of Epidermal Growth Factor Receptor Inhibitor Efficacy in Colorectal Cancer
Screening colorectal tumors for the absence of KRAS mutations may help identify patients most likely to benefit from anti-EGFR therapies.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select patients who are eligible for the treatment and should be used for selection.
Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer
The aim is to identify molecular markers that might be used to select patients with the higher probability of response to anti-EGFR moAbs, and to identify clinicians more rational options for treating this illness.
Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
There is a need of careful consideration of previously published results of anti-EGFR-targeted therapy with regard to potentially inaccurate diagnostic tools used in the past, as it brings a significant added value in terms of validity of the diagnostic procedure.
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
TP53 mutations are predictive of cetuximab sensitivity, particularly in patients without KRAS mutation, and that TP53 genotyping could have a clinical interest to select patients who should benefit from cetUXimab-based CT.
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer
EGFR gene amplification and KRAS mutations are predictive markers for patients receiving combination biologic therapy of cetuximab plus bevacizumab for metastatic colorectal cancer allowing treatment response to be predicted with a high degree of certainty.
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ra did benefit fromcetuxIMab.
Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab
The study suggests that activating KRAS mutants is a particularly important independent predictive marker in mCRC patients treated with cetuximab plus chemotherapy, of which combing activatingKRAS mutants and EGFR could help to identify the subgroup of patients who are most likely to respond to cetUXimabplus chemotherapy.


Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer
Purpose: Recently, activating mutations of the epidermal growth factor receptor (EGFR) gene were discovered in non–small cell lung cancers sensitive to gefitinib (ZD1839, an EGFR tyrosine kinase
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
  • K. Chung, J. Shia, L. Saltz
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Colorectal cancer patients with EGFR-negative tumors have the potential to respond to cetuximab-based therapies, and selection or exclusion of patients for cetUXimab therapy on the basis of currently available EGFR IHC does not seem warranted.
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Cetuximab on this once-weekly schedule has modest activity and is well-tolerated as a single agent in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor.
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.
Ki-ras mutations are associated with increased risk of relapse and death, but some mutations are more aggressive than others.
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study
It is shown that only a small fraction of epidermal growth factor receptor- positive colorectal carcinomas detected by IHC are associated with gene amplification, and furthermore, all tumors that did not express the protein by I HC lacked gene amplification.
Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti‐EGFR therapy?
Aims : To investigate EGFR gene copy number heterogeneity in colorectal carcinomas compared with copy number of chromosome 7 and immunohistochemical expression of the EGFR protein.
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
To determine if PI3Ks are genetically altered in tumorigenesis, they were sequenced in human for the first time and the results allowed us to assess the importance of phosphatidylinositol 3-kinases in neoplasia.
The price tag on progress--chemotherapy for colorectal cancer.
  • D. Schrag
  • Medicine
    The New England journal of medicine
  • 2004
The irinotecan and cetuximab regimen costs approximately $30,790. How should we determine whether these interventions are worth their immense cost? Dr. Deborah Schrag responds.